Low concentration atropine eye drops and progression of myopia in children: multicentre placebo controlled, double masked, randomised trial in the UK (CHAMP-UK)
Listen to this summary
The study aimed to evaluate the efficacy and safety of low concentration atropine eye drops (0.01%) in reducing myopia progression in children aged 6-12 years in the UK. The results demonstrated that atropine significantly reduced myopia progression compared to placebo, with no serious adverse events reported, indicating it is a well-tolerated treatment option for managing myopia in this population.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from BMJ (Clinical research ed.)
View all →Jun 24, 2026 · BMJ (Clinical research ed.)
Assessing early effects of Australia's Social Media Minimum Age Act on adolescents' social media use: observational study
Jun 18, 2026 · BMJ (Clinical research ed.)
Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR)
Jun 15, 2026 · BMJ (Clinical research ed.)
Advances in the development of malaria vaccines
Jun 10, 2026 · BMJ (Clinical research ed.)
Advances in supporting development in autistic children and youth
Jun 8, 2026 · BMJ (Clinical research ed.)
Advances in the management of ADHD in children and adolescents
Jun 4, 2026 · BMJ (Clinical research ed.)
Global, regional, and national levels and trends in under 5, infant, and neonatal mortality during 1990-2024 with scenario based projections to 2030: modelling study
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
